Ibrutinib
Showing 1 - 25 of 368
Cardiovascular Complications of Ibrutinib Therapy
Not yet recruiting
- Ibrutinib Treatment
- ophthalmological examination
- blood test
-
Dijon, FranceChu Dijon Bourgogne
Jul 3, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Lymphoma
- Ibrutinib
- Venetoclax
- (no location specified)
Jul 19, 2023
Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)
Not yet recruiting
- Mantle Cell Lymphoma Refractory
- Ibrutinib
- +3 more
- (no location specified)
May 16, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))
Active, not recruiting
- Glioblastoma
- Ibrutinib
- +2 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023
Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
- BNC105P
- Ibrutinib
-
Lebanon, New HampshireDartmouth-Hitchcock Medical Center
Jan 3, 2023
Chronic Lymphocytic Leukemia Trial (Evaluation of response to treatment with response-tailored Ibrutinib in patients with
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia
- (no location specified)
Dec 27, 2022
Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
-
Augusta, GeorgiaAugusta University, Georgia Cancer Center
Dec 16, 2022
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Recruiting
- PCNSL
- Ibrutinib
-
Milan, ItalyOspedale San Raffaele
Mar 13, 2023
Chronic GVHD Trial in Bethesda, Saint Louis (Ibrutinib)
Recruiting
- Chronic GVHD
- Ibrutinib
-
Bethesda, Maryland
- +1 more
Jan 26, 2023
Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in
Active, not recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
- Ibrutinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2023
Mantle Cell Lymphoma Trial in Houston (Ibrutinib)
Recruiting
- Mantle Cell Lymphoma
- Ibrutinib
-
Houston, TexasM D Anderson Cancer Center
Nov 1, 2022
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Ibrutinib 420 mg)
Not yet recruiting
- Autoimmune Hemolytic Anemia
- +3 more
- Ibrutinib 420 mg
- (no location specified)
Jan 12, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)
Completed
- Waldenstrom's Macroglobulinemia
- Ibrutinib
-
Boston, Massachusetts
- +1 more
Dec 5, 2022
Unfit CLL Included in GIMEMA LLC1114 Trial Who Discontinued
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Observation
- (no location specified)
Oct 12, 2023
CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)
Recruiting
- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- +2 more
- Ibrutinib
- Nivolumab
-
Houston, TexasM D Anderson Cancer Center
Dec 13, 2022
Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)
Active, not recruiting
- Mantle Cell Lymphoma Recurrent
- ibrutinib and Tisagenlecleucel
-
Melbourne, Victoria, AustraliaPeter Mac Callum Cancer Centre
Nov 4, 2022
Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)
Recruiting
- Graft Vs Host Disease
- Rituximab
- Ibrutinib
-
Atlanta, GeorgiaNorthside Hospital
Oct 19, 2022
T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)
Active, not recruiting
- T-cell Lymphoma
- Relapsed and Refractory T-cell Lymphoma
- Ibrutinib
-
New York, New York
- +1 more
Nov 8, 2022
Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),
Active, not recruiting
- Head and Neck Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Ibrutinib 560mg PO daily (Imbruvica)
- +2 more
-
La Jolla, CaliforniaUCSD Moores Cancer Center
Jan 11, 2023
Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2022
Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)
Terminated
- Diffuse Large B-cell Lymphoma
- Tisagenlecleucel
- Ibrutinib
-
Tampa, Florida
- +1 more
Jan 27, 2023
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
-
Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022